XNYS · Healthcare · Drug Manufacturers - General
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-27 | Q2 2026 | 1.52 | 2.63 | +73.03% | $15.38B | ✅ Beat | +0.57% | -6.88% | -1.99% |
| 2026-04-29 | Q1 2026 | 1.53 | 2.58 | +68.63% | $15.29B | ✅ Beat | -0.68% | -0.15% | +0.25% |
| 2026-02-10 |
| Q4 2025 |
| 2.18 |
| 2.12 |
| -2.75% |
| $15.50B |
| ❌ Miss |
| +1.99% |
| +8.31% |
| -0.47% |
| 2025-11-06 | Q3 2025 | 1.14 | 1.19 | +4.39% | $15.19B | ✅ Beat | — | — | — |
| 2025-07-29 | Q2 2025 | 1.10 | 1.08 | -1.36% | $14.46B | ❌ Miss | — | — | — |
| 2025-04-29 | Q1 2025 | 1.11 | 1.25 | — | $13.59B | ✅ Beat | +0.11% | -2.02% | -1.17% |
| 2025-02-06 | Q4 2024 | 1.07 | 1.04 | -2.34% | $14.89B | ❌ Miss | -0.51% | +2.89% | +5.02% |
| 2024-11-12 | Q3 2024 | 1.03 | 1.04 | +0.97% | $13.56B | ✅ Beat | +0.15% | -2.13% | +2.68% |
Showing last 8 quarters.